This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. ICD-10 code | E83.3 | Special Copayment Reduction: V189 |
| B. Synonyms | Tissue-nonspecific alkaline phosphatase deficiency, hypophosphatasia, HPP, Phosphoethanolaminuria, TNSALP deficiency |
| C. Adult onset | Possible first presentation in adulthood — the adult form presents after middle age with stress fractures, fatigue fractures, premature tooth loss, myalgia, and muscle weakness, and diagnosis is often delayed for decades |
| 1. History | First described by Rathbun in 1948; history up to the discovery of the ALPL gene and development of enzyme therapy |
| 2. Causes | ALPL gene mutation → deficient TNSALP activity → accumulation of the substrates PPi, PLP, and PEA |
| 3. Genetics | Autosomal recessive (severe forms) or dominant (mild forms); more than 500 ALPL variants identified |
| 4. General epidemiology | Prevalence of severe perinatal/infantile forms 1/100,000; estimated 1/6,000 including mild forms |
| 5. Pathophysiology | PPi accumulation → inhibition of bone mineralization; reduced PLP → vitamin B6-dependent seizures |
| 6. Symptoms | 6 clinical forms (perinatal/infantile/childhood/adult/odonto/benign); fractures, seizures, premature tooth loss |
| 7. Signs | Low serum ALP, skeletal deformities, craniosynostosis, short stature, abnormal calcification |
| 8. Screening | Serum ALP measurement; consider inclusion in newborn screening |
| 9. Diagnosis | Low ALP + elevated substrates (PLP, PEA, PPi) + confirmation of ALPL gene variant |
| 10. Treatment | Asfotase alfa enzyme replacement therapy; supportive care |
| 11. Prognosis | High mortality in perinatal/infantile forms before treatment; dramatic improvement with enzyme replacement therapy |
| 12. Prevention | Carrier testing, prenatal genetic counseling, family screening |
| 13. References | 10 key references |
Hypophosphatasia (HPP) is a congenital metabolic disease first described in 1948 by the Canadian pediatrician John Campbell Rathbun. Rathbun found extremely low serum alkaline phosphatase (ALP) activity in a newborn who died with severe skeletal abnormalities and seizures, and named it "hypophosphatasia". Initially it was sometimes regarded as a variant of simple rickets, but later, detection of large amounts of the ALP substrate phosphoethanolamine (PEA) in the urine confirmed it to be an independent enzyme deficiency disease.
In the 1950s–1960s, with advances in serum ALP measurement techniques, a mild form (odonto form) characterized by premature tooth loss was described separately, and the adult form also came to be recognized as an independent clinical subtype. In 1985, the human ALPL gene (encoding tissue-nonspecific alkaline phosphatase, TNSALP) was cloned, and hundreds of pathogenic variants were subsequently identified. In 1992, Whyte et al. attempted ALP-rich bone marrow transplantation in short-lived infant HPP patients, but the clinical effect was limited.
In the 2000s, studies using mouse models revealed that accumulation of inorganic pyrophosphate (PPi) is the key mechanism of impaired bone mineralization. Based on this discovery, in the early 2010s Alexion Pharmaceuticals developed asfotase alfa (Strensiq®), a bone-targeted recombinant TNSALP protein, and in 2015 it received approval from the US FDA and the European EMA, introducing the world's first enzyme replacement therapy for HPP into clinical practice. This approval is regarded as a very important milestone in the history of rare disease treatment.
In Korea, it is designated under Special Copayment Reduction code V189, and because the number of patients in Korea is extremely small, diagnosis itself is often delayed. Recently, as awareness of adult HPP has increased, the clinical practice of checking serum ALP in adult patients presenting with recurrent fractures, fatigue fractures, and musculoskeletal pain has been recommended.
The direct cause of hypophosphatasia is reduced or absent activity of the tissue-nonspecific alkaline phosphatase (TNSALP) enzyme due to pathogenic variants in the ALPL (alkaline phosphatase, liver/bone/kidney) gene. TNSALP is a zinc- and magnesium-dependent metalloenzyme bound to the cell surface by a GPI anchor (glycosylphosphatidylinositol anchor), expressed mainly in the liver, bone, kidney, and developing neural tissue.
TNSALP has three main physiological substrates. First, inorganic pyrophosphate (PPi) is an inhibitor of bone mineralization, and TNSALP hydrolyzes it to supply the phosphate (Pi) needed for bone mineralization. When TNSALP is deficient in HPP, PPi accumulates in the extracellular space and hydroxyapatite crystal formation is inhibited. Second, pyridoxal 5'-phosphate (PLP), the phosphorylated form of vitamin B6, must be hydrolyzed by TNSALP to be transported into cells. When PLP accumulates extracellularly, intracellular PLP deficiency develops in neurons, reducing γ-aminobutyric acid (GABA) synthesis and inducing vitamin B6-dependent seizures. Third, phosphoethanolamine (PEA), a metabolite of cell membrane phospholipids, is elevated in blood and urine.
Secondary causes include drug-induced hypophosphatasemia (low ALP). Zinc excess, clopamide, antiepileptic drugs (especially valproic acid), hypothyroidism, severe anemia, pernicious anemia, etc. can temporarily lower serum ALP, but this is not true HPP. Clinicians should confirm recurrent and persistent low serum ALP and interpret it against age-specific normal reference ranges.
HPP is a monogenic disease caused by ALPL gene variants. The ALPL gene is located on the short arm of chromosome 1 (1p36.12) and consists of 12 exons. The protein functions as a homodimer of 524 amino acids. As of 2024, more than 500 pathogenic ALPL variants are registered in the HPP Database (SESEP), of which missense variants account for about 70%.
The mode of inheritance is closely related to the phenotype. Severe forms (perinatal and infantile) are mostly inherited in an autosomal recessive (AR) manner, with pathogenic variants in both alleles. In contrast, mild forms (odonto, adult, benign perinatal) can also manifest as autosomal dominant (AD), in which case one variant allele interferes with the function of the normal allele product through a dominant-negative effect. This phenomenon occurs because TNSALP functions as a homodimer.
The most frequently identified pathogenic variants include p.Ala162Val, p.Asp361Val, p.Glu191Lys, and p.Gly317Asp, but the variant distribution varies among ethnic groups. A variant spectrum different from Western populations has been reported in East Asian patients, and systematic variant analysis data for Korean patients are still limited. The carrier frequency for the severe AR form is estimated at about 1/300, and in some populations (such as the Canadian Mennonite community) specific founder mutations occur at high frequency.
Genotype-phenotype correlations are complex. Phenotypic differences can be large even among family members with the same variant, and modifier genes or environmental factors are presumed to play a role. Genetic testing is used for definitive diagnosis, carrier testing, prenatal diagnosis, and prediction of clinical subtype.
HPP is a panethnic disease occurring worldwide. The prevalence of the severe perinatal and infantile forms is estimated at about 1/100,000 births, and the overall prevalence including mild forms is reported as about 1/6,370 births. In the Mennonite population of western Canada, it is as high as 1/2,500 births due to a founder effect.
The difference in incidence by sex is not large, but odonto HPP tends to be diagnosed more often in women. This may also reflect diagnostic bias. The adult form is often misdiagnosed in middle-aged women as postmenopausal osteoporosis or recurrent fractures, delaying diagnosis. Because HPP is very rare worldwide, it is difficult for a single institution to see many patients, so global patient registries (ENi registry, HARMONY study, etc.) play an important role in collecting clinical epidemiological data.
Prevalence data for East Asia including Korea are limited, but according to Health Insurance Review & Assessment Service (HIRA) rare disease statistics, the number of registered patients in Korea is estimated at a few dozen. However, many mild cases go undiagnosed, so the actual prevalence is likely higher.
The pathophysiology resulting from TNSALP deficiency is explained mainly by extracellular accumulation of three substrates and the resulting downstream effects.
First, extracellular accumulation of inorganic pyrophosphate (PPi) is the key mechanism of impaired bone mineralization. Normally, PPi secreted by osteoblasts is broken down by TNSALP into Pi and Pi, promoting formation of hydroxyapatite (Ca₁₀(PO₄)₆(OH)₂) crystals. In HPP, PPi is not removed and accumulates, acting as a potent inhibitor of crystal formation. This manifests as osteomalacia and rickets, in which osteoid fails to calcify.
Second, matrix vesicle dysfunction occurs. Normally, matrix vesicles derived from osteoblasts are organelles enriched in TNSALP that raise internal calcium and phosphate concentrations to initiate hydroxyapatite crystal nucleation. Matrix vesicles deficient in TNSALP cannot adequately break down PPi, and their ability to initiate mineralization is markedly reduced.
Third, intracellular PLP deficiency causes neurological symptoms. PLP must be dephosphorylated to pyridoxal by TNSALP outside the cell to cross the cell membrane. When this process is impaired in HPP, PLP becomes deficient in neurons, and the activity of glutamate decarboxylase, which requires PLP as a cofactor, decreases, reducing GABA synthesis. GABA deficiency causes vitamin B6-dependent seizures (pyridoxine-responsive seizures).
Recent studies have also revealed that TNSALP deficiency impairs formation of dental cementum, which is the mechanism of premature tooth loss. Sharpey's fibers, which are central to the connection between alveolar bone and teeth, cannot attach to the dental cementum, so teeth are easily lost.
HPP is clinically classified into 6 main subtypes, with widely varying age of onset and severity.
Perinatal lethal form: manifests during pregnancy or immediately after birth and is the most severe. It is characterized by hydrops fetalis, shortened and deformed limbs, thoracic hypoplasia (pulmonary hypoplasia), and deficient skull mineralization. Most are stillborn or die of respiratory failure in the neonatal period. Shortening, bowing, and angulation of long bones are observed on ultrasound.
Benign perinatal form: limb bowing and skeletal deformities are present at birth but improve spontaneously; this form is often due to dominant variants, unlike the perinatal lethal form.
Infantile form: manifests within the first 6 months of life. Infants are initially normal but gradually develop feeding difficulties, growth retardation, hypotonia, recurrent vomiting, dehydration, hypercalcemia, and vitamin B6-dependent seizures. Craniosynostosis may occur, and mortality before treatment is high.
Childhood form: characterized by premature loss of primary (baby) teeth (before age 5, with the roots intact). Growth retardation, rachitic bone deformities, muscle weakness, and gait abnormalities may accompany it.
Adult form: manifests after middle age; the main symptoms are recurrent stress fractures (especially of the femur), fatigue fractures, chondrocalcinosis, arthralgia, myalgia, and fatigue. Many patients have a history of premature tooth loss in childhood.
Odontohypophosphatasia: the mildest form, in which only premature loss of primary teeth occurs without skeletal symptoms. Tooth loss is caused by weakening of the periodontal ligament, and permanent teeth are sometimes normal.
Benign hypercalcemic form: rarely, symptomatic hypercalcemia, vomiting, and dehydration occur in newborns, and HPP is diagnosed without skeletal abnormalities.
The clinical signs of HPP are very diverse and differ by form and age.
Skeletal signs: in the perinatal and infantile forms, defective skull mineralization (depressible skull), shortening and bowing of long bones, a narrow thorax, and rib fractures are observed. In the childhood form, varus or valgus deformities of the lower limbs, rachitic rosary, and irregular growth plates appear. In the adult form, femoral cortical pseudofractures (Looser zones), vertebral compression fractures, and chondrocalcinosis are seen on radiography.
Neurological signs: in the infantile form, vitamin B6-dependent seizures respond temporarily to pyridoxine (vitamin B6) administration, but this is not a definitive treatment. Signs of increased intracranial pressure due to craniosynostosis (papilledema, headache, etc.) may occur.
Dental signs: premature loss of primary teeth (before age 5) is the most characteristic. Examination of shed teeth often shows that they were lost with the roots fully intact. This is a point of differentiation from tooth loss due to other causes such as rickets.
Laboratory signs: serum ALP is significantly lower than the normal range for age and sex (caution: in infants and children the normal range is much higher than in adults). Serum PLP, urinary PEA, and plasma PPi are elevated. Serum calcium and phosphate may be normal or elevated. Parathyroid hormone (PTH) may be suppressed in response to hypercalcemia.
Imaging signs: bone X-rays show decreased bone density, irregular epiphyses, Looser zones, and asymmetric skull mineralization. Even on plain X-rays, an experienced radiologist can suspect HPP.
Currently, most countries do not have an official national newborn screening program for HPP. However, serum ALP measurement is used as the primary screening tool in clinically suspected situations.
Serum ALP measurement: the most basic and important screening test. In adults, recurrent ALP below 20 U/L (or below 50% of the lower limit of normal for age and sex) strongly suggests HPP. In children, normal ALP is several times higher than in adults, so applying age-specific reference ranges is essential. The upper limit of normal ALP in newborns is about ~700 IU/L, and in newborns with HPP it may be below 100 IU/L or undetectable.
Radiological screening: when bone shortening or bowing abnormalities are found on prenatal ultrasound, differentiation of skeletal dysplasias including HPP is needed. Long bone abnormalities may be observed from 15–16 weeks of gestation.
Family history screening: measurement of serum ALP and urinary PEA is recommended in first-degree relatives of HPP patients, especially siblings. ALPL gene analysis is also considered for carrier testing.
HPP should be considered in patients with recurrent fractures, premature tooth loss, or unexplained musculoskeletal pain when ALP on routine biochemical testing is low or near the lower limit of normal. Because ALP is included in the liver function test panel, it is sometimes found incidentally.
Definitive diagnosis of HPP is made by integrating clinical symptoms and signs, biochemical findings, and genetic testing.
Biochemical diagnosis: (1) Serum ALP: persistently decreased below the reference range for age and sex. Confirmed by repeated rather than single measurement. (2) Plasma PLP (pyridoxal-5'-phosphate): a natural substrate of TNSALP; plasma PLP ≥200 nmol/L (about 5 times or more the upper limit of normal) is a strong indicator of HPP. (3) Urinary PEA (phosphoethanolamine): elevated 24-hour urinary PEA is the classic biochemical marker of HPP, but its specificity is limited. (4) Plasma PPi: measurable only at some specialized institutions; elevation supports HPP.
Genetic diagnosis: pathogenic variants are identified by direct sequencing of the ALPL gene (Sanger sequencing or next-generation sequencing, NGS). Testing for multi-exon deletions/duplications should also be included. Pathogenicity classification of gene variants is performed according to ACMG criteria.
Imaging diagnosis: osteopenia, Looser zones, and cortical pseudofractures of long bones on skeletal X-rays support HPP. Bone densitometry (DXA) is useful for quantifying reduced bone density, but its diagnostic specificity is low.
Differential diagnosis: differentiation is needed from rickets (vitamin D deficiency, calcium deficiency), osteogenesis imperfecta, achondroplasia, Blount disease, and other causes of vitamin B6-dependent seizures. In particular, in differentiating from rickets, the key point is that ALP is low in HPP, whereas it is normal or elevated in vitamin D-deficiency rickets.
Enzyme Replacement Therapy (ERT): asfotase alfa (brand name Strensiq®) is a bone-targeted recombinant human TNSALP protein that received FDA and EMA approval in 2015. Dosing for children (under 5 years) is 1 mg/kg/dose by subcutaneous injection 6 times a week, or 2 mg/kg/dose 3 times a week; for children (5 years and older) to adults, 2 mg/kg/dose 3 times a week or 3 mg/kg/dose once a week. ERT has shown significant effects in the infantile and childhood forms, including improved bone mineralization, fewer seizures, improved growth and motor function, and improved respiratory function. In the adult form, reduced fracture risk and improved musculoskeletal symptoms are also reported, but long-term data are still accumulating.
Supportive treatment: (1) Vitamin B6 (pyridoxine): may be given to HPP infants with seizures for initial seizure control, but has no curative effect. (2) Calcium and vitamin D supplementation: caution is needed with calcium supplementation because hypercalcemia can occur in HPP. Vitamin D is used cautiously at usual doses. (3) Calcium-lowering treatment: for hypercalcemia, hydration, a low-calcium diet, and if needed a loop diuretic (furosemide) are considered. (4) Orthopedic treatment: fracture fixation, corrective surgery for bone deformities, and cranioplasty for craniosynostosis may be needed. (5) Dental care: after premature tooth loss, dentures (prostheses) support chewing function and speech development.
Treatments to avoid: bisphosphonates are PPi analogues that can further inhibit bone mineralization, so their use should be avoided in HPP patients. High-dose calcium and vitamin D also require caution because of the risk of hypercalcemia.
The prognosis of HPP differs markedly by clinical subtype and whether treatment is given.
Without treatment, the perinatal lethal form has a mortality close to 100% from stillbirth or neonatal respiratory failure. Since the introduction of asfotase alfa, survival has begun to be reported in some severe perinatal cases, but long-term outcome data are still lacking. In the infantile form, mortality before age 2 exceeded 50% before treatment, but survival has improved greatly since the introduction of ERT, and improvements in motor and respiratory function are being reported.
The long-term prognosis of the childhood form is relatively good, but without treatment growth retardation, recurrent fractures, and reduced mobility may persist. When craniosynostosis is present, early surgery determines the neurological outcome. In the adult form, shortened life expectancy is rare, but reduced quality of life, chronic pain from recurrent fractures, and reduced mobility are problems. The effect of ERT in adults is assessed positively in clinical trials, but accumulation of long-term follow-up data is needed.
The odonto form (the mildest) often does not greatly interfere with daily life, but impaired chewing, speech problems, and psychosocial effects due to premature tooth loss should be considered. Across all clinical types, regular multidisciplinary follow-up (endocrinology, orthopedics, dentistry, neurology, rehabilitation medicine) contributes to improved outcomes.
Because HPP is a monogenic disease, there is no specific method to prevent its occurrence. However, early identification of severe manifestations and prevention of complications are possible through genetic counseling and prenatal and perinatal management.
Genetic counseling: specialized genetic counseling is recommended when an HPP patient or carrier is planning a pregnancy. In the severe AR form, when both parents are carriers, a child is affected with a 25% probability. The AD form can be transmitted to children with a 50% probability.
Prenatal diagnosis: in families who have previously had a child with severe HPP, prenatal diagnosis is possible by ALPL gene analysis via chorionic villus sampling (CVS) or amniocentesis. When skeletal abnormalities are suspected on second-trimester prenatal ultrasound, molecular genetic testing is recommended.
Family screening: serum ALP and PLP measurement and ALPL gene testing are performed in siblings and parents of confirmed patients to enable early diagnosis and linkage to treatment.
Prevention of complications: in confirmed patients, bisphosphonate prescription is avoided, drugs that may cause hypercalcemia and a high-calcium diet are restricted, and fracture risk is minimized with regular skeletal follow-up examinations. Dental health care and appropriate use of prostheses are also important for improving quality of life.